ARID1B mutations promote immune evasion in acute myeloid leukemia through upregulating VISTA expression.
Blocking a specific immune checkpoint in AML cells with ARID1B mutations restores the immune system's tumor-fighting ability.
ARID1B loss-of-function mutations in AML cells upregulate the immune checkpoint VISTA, enabling immune evasion; pharmacological VISTA blockade restores T-cell-mediated antitumor immunity in ARID1B-mutant AML models. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Mechanistic basic science (in vitro/in vivo)
- Category
- Other
- Maturity
- Exploratory
- Journal
- International immunopharmacology
Why it surfaced
Novel chromatin-to-immunocheckpoint mechanism in AML with therapeutic implications; VISTA is increasingly targeted in clinical trials; ARID1B mutation frequency in AML makes this actionable for patient stratification.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.